The stock is up 38% on more than 11,000 trades with volume eclipsing 11 million shares. Current price .33
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
- Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibody
- Combination of SON-1010 with anti-PD1 increased survival rate
- These data will guide future combination study designs with SON-1010 and checkpoint inhibitors
PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, today announced data from a preclinical combination study of SON-1010 with a commercially available anti-PD1 compound. These results suggest that dosing of SON-1010 (IL12- FHAB) in combination with anti-PD1 demonstrated strong efficacy in the B16F10 mouse melanoma model, historically known as an immunologically insensitive model to anti-PD1.